Zheng et al., 2016 - Preclinical evaluation of a novel orally available SRC/Raf/VEGFR2 inhibitor, SKLB646, in the treatment of triple negative breast cancer. Molecular cancer therapeutics   15(3):366-78 Full text @ Mol. Cancer Ther.
Human Disease / Model Data (1 Record)
Human Disease Fish Environment Evidence Code
triple-receptor negative breast cancer
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.